


What we claim is,


1. Use of the compounds of the general Formula



(wherein

R^1 stands for hydrogen or lower alkyl;

one of symbols X and Y stands for hydrogen or halogen and the other represents a group of the general Formula



R^2 is hydrogen or lower alkyl;

n is 1, 2 or 3;

R^3 is hydrogen, lower alkyl or aryl-lower alkyl;

Z is -O-; or

R^3 and Z together with the intermediate atoms form a piperazino ring;

Q and W independently from each other stands for -CH= or -N=; and

R^4 , R^5 and R^6 can be the same or different and stand for hydrogen, halogen, trifluoromethyl or lower alkoxy; or R^4 and R^5 together form an ethylenedioxy group) and pharmaceutically acceptable salts thereof for the preparation of pharmaceutical compositions suitable for the treatment and/or prophylaxis of malfunctions of memory and/or cognitive decline or prevention of decline of learning abilities.

2. Use according to Claim 1 for the preparation of pharmaceutical compositions suitable for the treatment or prophylaxis of Korsakoff syndrome, Alzheimer disease, Huntington syndrome or Parkinson disease and/or mental decline due to ageing processes or impairment of the cognitive functions due to exposure to toxical substances.

3. Use according to Claim 1 or 2 which comprises using as active ingredient a compound of the general Formula I or a pharmaceutically acceptable acid addition salt thereof in which

R^1 is hydrogen, methyl, ethyl or tertiary butyl;
one of symbols X and Y is hydrogen or chlorine and the other represents a group of the general Formula II;

R^2 is hydrogen or methyl;

n is 1 or 2;

R^3 is hydrogen, methyl or benzyl;

Z is -O-; or

R³ and Z together with the intermediate atoms form a piperazino ring;

R⁴, R⁵ and R⁶ can be the same or different and stand for hydrogen or halogen; or R⁴ and R⁵ together form an ethylenedioxy group); and

Q and W stand for -CH=.

4. Use according to Claim 1 which comprises using as active ingredient 4-(3-((2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethyl)-methyl-amino)-propyl-amino)-5-chloro-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

5. Use according to Claim 1 which comprises using as active ingredient 4-(3-{[2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethyl]-propyl-amino}-propylamino)-5-chloro-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

6. Use according to Claim 1 which comprises using as active ingredient 4-(3-(benzil-(2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethyl)-amino)-propyl-amino)-5-chloro-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

7. Use according to Claim 1 which comprises using as active ingredient 4-(4-(4-(2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl)-butylamino)-5-chloro-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

8. Use according to Claim 1 which comprises using as active ingredient 5-(2-(4-(2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl)-ethyl-amino)-4-chloro-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

9. Use according to Claim 1 which comprises using as active ingredient 4-chloro-5-(2-(4-(2,3-dihydro-1,4-benzodioxine-5-yl)-piperazine-1-yl)-ethylamino)-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

10. Use according to Claim 1 which comprises using as active ingredient 4-chloro-5-((2-(4-(2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl)-ethyl)-methyl-amino-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

11. Use according to Claim 1 which comprises using as active ingredient 2-*tert.*-butyl-5-chloro-4-(2-(4-(2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl)-ethylamino)-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
12. Use according to Claim 1 which comprises using as active ingredient 4-(3-(2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethylamino)-propylamino)-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
13. Use according to Claim 1 which comprises using as active ingredient -{2-[4-(2,3-dihydro-1,4-benzodioxine-5-yl)-piperazine-1-yl]-ethyl-amino}-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
14. Use according to Claim 1 which comprises using as active ingredient 5-{2-[4-(7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl]-ethylamino}-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
15. Use according to Claim 1 which comprises using as active ingredient 5-{3-[4-(2,3-dihydro-1,4-benzodioxine-5-yl)-piperazine-1-yl]-propylamino}-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

16. Use according to Claim 1 which comprises using as active ingredient -(2-(2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethylamino)-ethyl-amino)-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
17. Use according to Claim 1 which comprises using as active ingredient 5-{2-[4-(2,3-dihydro-1,4-benzodioxine-5-yl)-piperazine-1-yl]-ethyl-amino}-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
18. Use according to Claim 1 which comprises using as active ingredient 5-({2-[4-(2,3-dihydro-benzo[1,4]dioxine-5-yl)-piperazine-1-yl]-ethyl}-methyl-amino)-2H-pyridazine-3-one hydrochloride or monohydrate thereof or a pharmaceutically acceptable salt thereof.
19. Use according to Claim 1 which comprises using as active ingredient 5-(2-(4-(2,3-dihydro-benzol[1,4]dioxine-5-yl)piperazine-1-yl)-ethyl-methylamino)-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.
20. Use according to Claim 1 which comprises using as active ingredient 5-({2-[4-(2,3-dihydro-

benzo[1,4]dioxine-5-yl)-piperazine-1-yl]-ethyl}-methyl-amino)-4-chloro-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

21. Use according to Claim 1 which comprises using as active ingredient 5-(2-{benzyl-[2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethyl]-amino}-ethylamino)-4-chloro-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

22. Use according to Claim 1 which comprises using as active ingredient 5-{2-[2-(2,3-dihydro-benzo[1,4]dioxine-5-yloxy)-ethylamino]-ethyl-amino}-2-methyl-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

23. Use according to Claim 1 which comprises using as active ingredient 5-{2-[4-(metoxi-trifluoromethyl-phenyl)-piperazine-1-yl]-ethylamino}-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

24. Use according to Claim 1 which comprises using as active ingredient 5-(2-[4-(2-fluoro-phenyl)-piperazine-1-yl]-ethylamino)-2H-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

25. Use according to Claim 1 which comprises using as active ingredient 5-(2-[4-phenyl-piperazine-1-yl]-ethylamino)-2*H*-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

26. Use according to Claim 1 which comprises using as active ingredient 5-[2-(4-pyridin-2-yl-piperazine-1-yl)-ethylamino]-2*H*-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

27. Use according to Claim 1 which comprises using as active ingredient 5-[2-(4-pyrimidine-2-yl-piperazine-1-yl)-ethylamino]-2*H*-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

28. Use according to Claim 1 which comprises using as active ingredient 5-{2-[4-(3-chloro-phenyl)-piperazine-1-yl]-ethylamino}-2*H*-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

29. Use according to Claim 1 which comprises using as active ingredient 5-{2-[4-(4-fluoro-phenyl)-piperazine-1-yl]-ethylamino}-2*H*-pyridazine-3-one or a pharmaceutically acceptable salt thereof.

30. Pharmaceutical composition suitable for the treatment and/or prophylaxis of malfunctions of memory and/or cognitive decline or prevention of decline of learning abilities comprising as active ingredient a compound of the general Formula I (wherein the substituents are as stated in Claim 1) or a pharmaceutically acceptable acid addition salt thereof in admixture with suitable inert solid or liquid pharmaceutical carriers and/or auxiliary agents.

31. Process for the treatment or prophylaxis of malfunctions of memory and/or cognitive decline or prevention of decline of learning abilities which comprises administering to the patient in need of such treatment a pharmaceutically efficient amount of the compound of the general Formula I or an acid addition salt thereof.